

Mark Garzotto

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2656019/publications.pdf>

Version: 2024-02-01

24
papers

294
citations

933447

10
h-index

888059

17
g-index

26
all docs

26
docs citations

26
times ranked

492
citing authors

#	ARTICLE	IF	CITATIONS
1	Sulforaphane Bioavailability and Chemopreventive Activity in Men Presenting for Biopsy of the Prostate Gland: A Randomized Controlled Trial. <i>Nutrition and Cancer</i> , 2020, 72, 74-87.	2.0	41
2	Phase 1/2 study of preoperative docetaxel and mitoxantrone for high-risk prostate cancer. <i>Cancer</i> , 2010, 116, 1699-1708.	4.1	38
3	Chemotherapy-Induced Monoamine Oxidase Expression in Prostate Carcinoma Functions as a Cytoprotective Resistance Enzyme and Associates with Clinical Outcomes. <i>PLoS ONE</i> , 2014, 9, e104271.	2.5	30
4	Neoadjuvant mitoxantrone and docetaxel for high-risk localized prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2006, 24, 254-259.	1.6	29
5	Cyclooxygenase-2 (COX-2) inhibition for prostate cancer chemoprevention: double-blind randomised study of pre-prostatectomy celecoxib or placebo. <i>BJU International</i> , 2017, 119, 709-716.	2.5	24
6	Phytol and its metabolites phytanic and pristanic acids for risk of cancer: current evidence and future directions. <i>European Journal of Cancer Prevention</i> , 2020, 29, 191-200.	1.3	24
7	Effects of ω -3 Fatty Acids and Catechins on Fatty Acid Synthase in the Prostate: A Randomized Controlled Trial. <i>Nutrition and Cancer</i> , 2016, 68, 1309-1319.	2.0	21
8	Circulating tumor cell (CTC) counts and CTC telomerase activity (TA) as prognostic markers of overall survival (OS) in SWOG S0421: Docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2012, 30, 1-1.	1.6	21
9	Optimizing the Sequence of Chemotherapy for Upper Tract Urothelial Carcinoma with Clinically Positive Regional Lymph Nodes. <i>Journal of Urology</i> , 2019, 202, 76-82.	0.4	13
10	Contemporary Management of High-risk Localized Prostate Cancer. <i>Current Urology Reports</i> , 2010, 11, 159-164.	2.2	11
11	SWOG S0421: Phase III study of docetaxel (D) and atrasentan (A) versus docetaxel and placebo (P) for men with advanced castrate resistant prostate cancer (CRPC).. <i>Journal of Clinical Oncology</i> , 2012, 30, 4511-4511.	1.6	10
12	Dairy Product Consumption and Prostate Cancer Risk in the United States. <i>Nutrients</i> , 2019, 11, 1615.	4.1	9
13	SYNDROME OF INAPPROPRIATE ANTIDIURETIC HORMONE SECRETION: A RARE COMPLICATION OF PROSTATE CANCER. <i>Journal of Urology</i> , 2001, 166, 1386-1386.	0.4	8
14	Endorectal MR imaging of prostate cancer: Evaluation of tumor capsular contact length as a sign of extracapsular extension. <i>Clinical Imaging</i> , 2018, 50, 280-285.	1.5	7
15	Unconventional Bladder Preservation: Factors Predicting Failure to Receive Definitive Surgery following Chemotherapy for Nonmetastatic Muscle Invasive Bladder Cancer in the National Cancer Database. <i>Journal of Urology</i> , 2018, 200, 535-540.	0.4	4
16	The estimated prevalence of missed positive lymph nodes based on extent of lymphadenectomy at radical prostatectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 574.e1-574.e9.	1.6	3
17	Advances in the Multimodality Management of High-risk Prostate Cancer. <i>Surgical Oncology Clinics of North America</i> , 2013, 22, 375-394.	1.5	1
18	Reply to neoadjuvant therapy followed by prostatectomy for clinically localized prostate cancer. <i>Cancer</i> , 2008, 112, 2519-2519.	4.1	0

#	ARTICLE	IF	CITATIONS
19	EDITORIAL COMMENT. Urology, 2020, 145, 157.	1.0	0
20	Editorial Comment. Journal of Urology, 2021, 205, 1688-1688.	0.4	0
21	The safety of prostate biopsy procedures in the research setting: A 10-year multicenter experience.. Journal of Clinical Oncology, 2012, 30, 87-87.	1.6	0
22	Circulating tumor cell counts (CTC) as prognostic of overall survival (OS) in SWOG S0421-docetaxel with or without atrasentan for metastatic castration resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2012, 30, 10503-10503.	1.6	0
23	Results of telomerase activity measurements from live circulating tumor cells captured on a slot microfilter in a phase III SWOG-coordinated prostate cancer trial (S0421).. Journal of Clinical Oncology, 2012, 30, 4663-4663.	1.6	0
24	Genomic analysis of prostate cancer.. Journal of Clinical Oncology, 2013, 31, 80-80.	1.6	0